- •2 tools measuring misuse, abuse, & related events in clinical trials are available.
- •SR-MAD can be easily implemented, but may lead to event underreporting.
- •At present, MADDERS is best suited to assessing events in clinical trials.
- •Additional study of these 2 tools in prospective randomized trials is needed.
- A comparison of the abuse liability of tramadol, NSAIDs, and hydrocodone in patients with chronic pain.J Pain Symptom Manage. 2006; 31: 465-476
- The prescribed opioids difficulties scale: A patient-centered assessment of problems and concerns.Clin J Pain. 2010; 26: 489-497
- Cross validation of the current opioid misuse measure to monitor chronic pain patients on opioid therapy.Clin J Pain. 2010; 26: 770-776
- Validation of a screener and opioid assessment measure for patients with chronic pain.Pain. 2004; 112: 65-75
- Principles of laboratory assessment of drug abuse liability and implications for clinical development.Drug Alcohol Depend. 2009; 105: S14-S25
- Prescription opiate abuse in chronic pain patients: Clinical criteria, incidence, and predictors.Clin J Pain. 1997; 13: 150-155
- Screening for addiction in patients with chronic pain and “problematic” substance use: Evaluation of a pilot assessment tool.J Pain Symptom Manage. 1998; 16: 355-363
European Medicines Agency: Guideline on the Clinical Development of Medicinal Products Intended for the Treatment of Pain. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/05/WC500143769.pdf. Accessed October 11, 2016
- Aberrant behaviors with prescription opioids and problem drug use history in a community-based cohort of HIV-infected individuals.J Pain Symptom Manage. 2011; 42: 893-902
- Opioid analgesic misuse is associated with incomplete antiretroviral adherence in a cohort of HIV-infected indigent adults in San Francisco.AIDS Behav. 2014; 18: 1352-1358
- Prescription Opioid Misuse Index: A brief questionnaire to assess misuse.J Subst Abuse Treat. 2008; 35: 380-386
- Screening for controlled substance abuse in interventional pain management settings: Evaluation of an assessment tool.Pain Physician. 2003; 6: 425-433
- The role of adverse events and related safety data in the pre-market evaluation of drug abuse potential.Drug Alcohol Depend. 2010; 112: 173-177
- The Fifth Edition of the Addiction Severity Index.J Subst Abuse Treat. 1992; 9: 199-213
- Predicting aberrant drug behavior in patients treated for chronic pain: Importance of abuse history.J Pain Symptom Manage. 2004; 28: 250-258
- Abuse liability measures for use in analgesic clinical trials in patients with pain: IMMPACT recommendations.Pain. 2013; 154: 2324-2334
- A new tool to assess and document pain outcomes in chronic pain patients receiving opioid therapy.Clin Ther. 2004; 26: 552-561
- The Columbia-Suicide Severity Rating Scale: Initial validity and internal consistency findings from three multisite studies with adolescents and adults.Am J Psychiatry. 2011; 168: 1266-1277
- Columbia Classification Algorithm of Suicide Assessment (C-CASA): Classification of suicidal events in the FDA’s pediatric suicidal risk analysis of antidepressants.Am J Psychiatry. 2007; 164: 1035-1043
- Assessing abuse liability during drug development: Changing standards and expectations.Clin Pharmacol Ther. 2008; 83: 622-626
Setnik B, Roland CL: A self-reported instrument to measure misuse, abuse, and diversion (SR-MAD) of prescription opioids. Presented at the ALERTT working group meeting, Washington, DC, June 27-28, 2013
Setnik B, Roland CL: Results from a chronic pain prescription opioid misuse, abuse, and diversion self-report instrument. Presented at the 31st Annual Meeting of the American Pain Society, Honolulu, HI, May 16-19, 2012
- The content validation of the Self-Reported Misuse, Abuse and Diversion (SR-MAD) of prescription opioids instrument for use in patients with acute or chronic pain.Current Med Res Opinion. 2017; 33: 1067-1076
- Prescription opioid abuse and misuse: Gap between primary-care investigator assessment and actual extent of these behaviors among patients with chronic pain.Postgrad Med. 2017; 129: 5-11
- A multicenter, primary care-based, open-label study to identify behaviors related to prescription opioid misuse, abuse, and diversion in opioid-experienced patients with chronic moderate-to-severe pain.J Pain Res. 2015; 8: 361-373
- The drug abuse screening test.Addict Behav. 1982; 7: 363-371
- Classification and definition of misuse, abuse, and related events in clinical trials: ACTTION systematic review and recommendations.Pain. 2013; 154: 2287-2296
- Instruments to identify abuse potential of prescription medications in clinical trials: ACTTION systematic review.J Pain. 2015; 16: 266-305
- Development and feasibility of the misuse, abuse, and diversion drug event reporting system (MADDERS(R)).Am J Addict. 2016; 25: 641-651
- Research design considerations for clinical studies of abuse-deterrent opioid analgesics: IMMPACT recommendations.Pain. 2012; 153: 1997-2008
U.S. Department of Health and Human Services, Office of Disease Prevention and Health Promotion: National Action Plan for Adverse Drug Event Prevention. Available at: http://health.gov/hcq/pdfs/ADE-Action-Plan-508c.pdf. Accessed October 11, 2016
U.S. Food and Drug Administration: Assessment of Abuse Potential of Drugs. Guidance for Industry. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM198650.pdf. Accessed October 11, 2016
US Food and Drug Administration: Guidance for Industry. Suicidal Ideation and Behavior: Prospective Assessment of Occurrence in Clinical Trials. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM225130.pdf. Accessed October 11, 2016
- Psychiatric history and psychologic adjustment as risk factors for aberrant drug-related behavior among patients with chronic pain.Clin J Pain. 2007; 23: 307-315
- The addiction behaviors checklist: Validation of a new clinician-based measure of inappropriate opioid use in chronic pain.J Pain Symptom Manage. 2006; 32: 342-351
The views expressed in this article are those of the authors, and other than employees of Analgesic Solutions, none of the authors have financial conflicts of interest related to the specific issues discussed in this report. Analgesic Solutions developed the Misuse, Abuse, and Diversion Drug Event Reporting System with input from the other authors. Carl L. Roland and Beatrice Setnik were both employees of King Pharmaceuticals, later Pfizer Inc, during the development of the Self-Reported Misuse, Abuse, and Diversion instrument. The findings, conclusions, and recommendations contained in this report are those of the authors. No official endorsement by the U.S. Food and Drug Administration (FDA), the Centers for Disease Control and Prevention, or the pharmaceutical companies that provided unrestricted grants to support the activities of the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) public-private partnership with the FDA should be inferred. At the time of the consensus meeting on which this article is based, 7 of the authors were employed by one of the companies that provided unrestricted grants to ACTTION to support its activities, including the consensus meeting. These companies were Collegium Pharmaceutical, Inc, GW Pharmaceuticals, plc, Horizon Pharma, Inc, Janssen Scientific Affairs, LLC, Pfizer Inc, and Purdue Pharma LP. Authors of this article who were not employed by industry or government at the time of the meeting received travel stipends, hotel accommodations, and meals during the meeting provided by ACTTION. ACTTION has received research contracts, grants, or other revenue from the FDA, multiple pharmaceutical and device companies, and other sources. Preparation of this article was supported by ACTTION. No external funding was received for the meeting or the preparation of this article.